HEILBRONN, Germany--(BUSINESS WIRE)--XENIOS® AG, a commercial-stage medical device company, announced today that it has expanded its operations to include its rapidly grown R&D group and an integrated larger manufacturing capacity as the company continues its aggressive growth strategy.
The new XENIOS combined-manufacturing-and-R&D facility is located in Reutlingen, just 30+ miles (50 km) south of corporate headquarters in Heilbronn, in a regional cluster of universities, hospitals and biomedical research facilities that have a strong focus on medical device technology, basic science and engineering.
“Given that no other company except XENIOS is offering minimally invasive lung and heart therapies on one platform, and given that the XENIOS platform provides fundamental advantages for patients with its minimally invasive lung and heart therapies, XENIOS is growing rapidly,” said Georg Matheis, MD, Managing Director. “As a direct result of the recent significant cash infusion from existing investors led by Zukunftsfonds Heilbronn (ZFHN), which we announced in September, XENIOS is able to enlarge its commercial operations per plan.”
“We are focused on growing sales of our leading products in a highly profitable yet under-penetrated market,” added Jürgen Böhm, MD, Managing Director. “The XENIOS strategy is to grow a highly profitable business in the U.S. and Europe with upside potential in Asia. XENIOS is now generating significant revenues with a scalable business, direct sales in place in three EU countries, and global KOLs participating as product champions. The expansion of our manufacturing and R&D operations into a single facility near corporate headquarters is another big step in the successful execution of our growth strategy.”
XENIOS AG is a privately held company and the recognized technology leader in minimally invasive medical devices that unite one console, XENIOS®, with next-generation lung (novalung®) and heart (i-cor®) therapies into a single platform for a market with revenue potential of nearly $9 billion. The XENIOS platform is designed for physicians to treat the same patient who either has certain singular lung or heart issues, or has concomitant lung and heart issues, with one platform of minimally invasive products that do not require mechanical ventilation, sedation, and immobility. XENIOS AG is the only company that can make this claim.
